Autologous hematopoietic recovery after allogeneic hematopoietic stem cell transplantation: A case-based review

Xiumin Shi; Xiaoliang Liu; Yang Tang; Yehui Tan; Wei Han; Sujun Gao

doi:10.1016/j.trim.2023.101920

Autologous hematopoietic recovery after allogeneic hematopoietic stem cell transplantation: A case-based review

Transpl Immunol. 2023 Dec:81:101920. doi: 10.1016/j.trim.2023.101920. Epub 2023 Aug 28.

Authors

Xiumin Shi¹, Xiaoliang Liu¹, Yang Tang¹, Yehui Tan¹, Wei Han¹, Sujun Gao²

Affiliations

¹ Department of Hematology, the First Hospital of Jilin University, Changchun, China.
² Department of Hematology, the First Hospital of Jilin University, Changchun, China. Electronic address: sjgao@jlu.edu.cn.

PMID: 37648035
DOI: 10.1016/j.trim.2023.101920

Abstract

Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is widely applied for the treatment of hematologic malignancies, but autologous hematopoietic recovery (AR) after allo-HSCT is rare clinically, especially after myeloablative conditioning (MAC). The mechanism of AR remains unclear so far, but the prognosis for most patients is relatively good. Second transplantation is preferred after disease relapse. Starting from a real-life clinical case scenario, herein we reviewed some of the crucial issues of AR in light of recent refinements, and discussed our patients based on the current evidence.

Keywords: Allo-HSCT; Autologous hematopoietic recovery; Incidence; MAC; Prognosis.

Publication types

Review

MeSH terms

Graft vs Host Disease* / pathology
Hematologic Neoplasms* / therapy
Hematopoietic Stem Cell Transplantation*
Humans
Prognosis
Retrospective Studies
Transplantation Conditioning
Transplantation, Homologous